Watson W. Mark

SEC source: 0001437749-26-023808 · rdgdoc.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,700

Underlying: Common Stock · 78,700 shares

Expires 2036-07-16

F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant.

SEC source: 0001437749-26-023808 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,525

F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant.

SEC source: 0001437749-26-018385 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,125

SEC source: 0001437749-25-037051 · rdgdoc.xml · nonDerivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,125

F1 · date: This Form 4 is being filed late due to delays in receiving EDGAR access codes.

SEC source: 0001437749-25-037051 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,125

F1 · date: This Form 4 is being filed late due to delays in receiving EDGAR access codes.

SEC source: 0001437749-25-024250 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,125

SEC source: 0001437749-25-020571 · rdgdoc.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,400

Underlying: Common Stock · 95,400 shares

Expires 2035-06-13

F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary of the date of the grant.

SEC source: 0001437749-25-020571 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,125

F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary date of the grant.

SEC source: 0001437749-24-020694 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,125

SEC source: 0001437749-24-020095 · rdgdoc.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,400

Underlying: Common Stock · 95,400 shares

Expires 2034-06-11

F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary of the date of the grant.

SEC source: 0001437749-24-020095 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,125

F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary date of the grant.

SEC source: 0001437749-23-021507 · rdgdoc.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,224

Underlying: Common Stock · 44,224 shares

Expires 2033-06-26

F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2024 annual meeting of stockholders of the Issuer and June 26, 2024, the first anniversary of the date of the grant.

SEC source: 0001437749-23-021507 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,125

F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2024 annual meeting of stockholders of the Issuer and June 26, 2024, the first anniversary date of the grant.

SEC source: 0001437749-22-029843 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

SEC source: 0001437749-22-019446 · rdgdoc.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,448

Underlying: Common Stock · 88,448 shares

Expires 2032-08-03

F2 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of August 4, 2022, the date of the grantee's appointment as a director of Vaxart, Inc.

SEC source: 0001437749-22-019446 · rdgdoc.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,750

F1 · shares: Grant of shares upon vesting of restricted stock units. One third of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the third anniversary of the grant date.

SEC source: 0001103021-22-000075 · wf-form4_164798391255661.xml · derivative · entry 4

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 85,760 shares

Expires not disclosed

F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

SEC source: 0001103021-22-000075 · wf-form4_164798391255661.xml · derivative · entry 3

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 54,740 shares

Expires not disclosed

F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

SEC source: 0001103021-22-000075 · wf-form4_164798391255661.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,685 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3 · price: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F3 · derivative.exercise_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F3 · derivative.expiration_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

SEC source: 0001103021-22-000075 · wf-form4_164798391255661.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

SEC source: 0001103021-22-000025 · wf-form4_164367038088743.xml · derivative · entry 4

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,685

Underlying: Common Stock · 7,684 shares

Expires 2023-01-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan ("the Plan"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023.

SEC source: 0001103021-22-000025 · wf-form4_164367038088743.xml · derivative · entry 3

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,369

Underlying: Common Stock · 15,369 shares

Expires 2023-01-27

F1 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan ("the Plan"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023.

F1 · derivative.exercise_date: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan ("the Plan"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023.

SEC source: 0001103021-22-000025 · wf-form4_164367038088743.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,760

Underlying: Common Stock · 85,760 shares

Expires 2032-01-26

F2 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.

F3 · kind: The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023.

F3 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023.

SEC source: 0001103021-22-000025 · wf-form4_164367038088743.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,663

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan ("the Plan"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023.

SEC source: 0001127602-21-024398 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Sykes Enterprises, Incorporated (the "Company) entered into an Agreement and Plan of Merger dated as of June 17, 2021 (the "Merger Agreement") by and among the Company, Sitel Worldwide Corporation, a Delaware corporation ("Parent") and Florida Mergersub, Inc., a Florida corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). On August 27, 2021, Merger Sub merged with and into the Company, the separate corporate existence of Merger Sub ceased and the Company survived the merger as a direct wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, each share of Company common stock and restricted stock units that were outstanding as of the closing of the merger was converted into the right to receive an amount in cash equal to $54.00, without interest and is subject to any applicable withholding taxes.

F2 · shares: Represents 11,409 shares of Common Stock and 2,082 restricted stock units held by the Reporting Person. In connection with the closing of the transactions contemplated by the Merger Agreement, each share of Common Stock held by the Reporting Person and each share of Common Stock underlying a restricted stock unit subject to time-based vesting that was outstanding as of the closing of the merger was converted into the right of the Reporting Person to receive a cash payment of $54.00, without interest and subject to any applicable withholding taxes.

SEC source: 0001103021-21-000074 · wf-form4_162863407322242.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 30,000 shares

Expires 2022-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders.

SEC source: 0001103021-21-000074 · wf-form4_162863407322242.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-017319 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,409

SEC source: 0001127602-21-006885 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,715

SEC source: 0001127602-21-005650 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,534

SEC source: 0000899243-20-035202 · doc4.xml · derivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,306,452

Underlying: Common Stock · 1,306,452 shares

Expires 2030-12-22

SEC source: 0001127602-20-029784 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,534

SEC source: 0001127602-20-028900 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,353

SEC source: 0001127602-20-024085 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,353

SEC source: 0001103021-20-000138 · wf-form4_159786902244654.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,979

F1 · balance_after: On August 17, 2020, the Reporting Person sold an aggregate of 13,000 shares of the Issuer's Common Stock at a weighted average price of $5.18 per share. The highest sale price for the Common Stock was $5.21 per share and the lowest sale price was $5.17 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

SEC source: 0001127602-20-023525 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,172

SEC source: 0001103021-20-000123 · wf-form4_159717910450200.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 30,000 shares

Expires 2022-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 30,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (ii) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders.

SEC source: 0001103021-20-000123 · wf-form4_159717910450200.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 30,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (ii) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders.

SEC source: 0001127602-20-017628 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,172

SEC source: 0001127602-20-016366 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,991

SEC source: 0001127602-20-012135 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,991

SEC source: 0000899243-20-009308 · doc4.xml · derivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,000

Underlying: Common Stock · 1,500,000 shares

Expires 2030-03-20

SEC source: 0001127602-20-007103 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,991

SEC source: 0001127602-20-006808 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,810

SEC source: 0000899243-20-003818 · doc5.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,054,100

SEC source: 0001127602-19-033522 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,827

SEC source: 0001127602-19-033462 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,646

SEC source: 0001127602-19-027206 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,662

SEC source: 0001127602-19-027138 · form4.xml · nonDerivative · entry 1

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,481

SEC source: 0001103021-19-000009 · wf-form4_156590093644021.xml · derivative · entry 2

Watson W. Mark · CIK 0001612372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,640

Underlying: Common Stock · 24,739 shares

Expires 2022-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 30,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (ii) 30,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iii) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders.